Core Viewpoint - Alpha Teknova, Inc. is set to report its financial results for the second quarter of 2025 on August 7, 2025, after market close, highlighting its ongoing role in the life sciences industry as a producer of critical reagents for novel therapies and diagnostics [1]. Group 1 - Teknova will host a webcast and conference call on August 7, 2025, at 5 p.m. Eastern Time, providing access through its Investor Relations section [2]. - The webcast will be available for replay on the company's website approximately two hours after the event [2]. Group 2 - Founded in 1996, Teknova specializes in manufacturing critical reagents for the life sciences sector, aiming to accelerate the discovery and development of new therapies [3]. - The company offers customizable solutions for various stages of the workflow, supporting sectors such as molecular diagnostics and synthetic biology [3]. - Teknova operates from a 180,000 square feet facility in Hollister, California, utilizing a modular manufacturing platform designed by experts to produce foundational ingredients for next-generation therapies [3].

Core Insights - Alpha Teknova, Inc. reported total revenue of $9.8 million for the first quarter of 2025, reflecting a 5% increase from $9.3 million in the same period of 2024 [1][5] - The company introduced the proprietary PluriFreeze™ cryopreservation system in collaboration with Pluristyx, Inc., enhancing its cell therapy product portfolio [1][8] - Teknova reaffirmed its revenue guidance for 2025, expecting total revenue between $39 million and $42 million [1][11] Financial Performance - Lab Essentials revenue reached $8.1 million, a 12% increase from $7.3 million in Q1 2024, while Clinical Solutions revenue decreased by 32% to $1.2 million from $1.7 million [4][5] - Gross profit for Q1 2025 was $3.0 million, with a gross margin of 30.7%, up from 23.8% in Q1 2024, driven by higher revenue and lower overhead costs [6] - Operating expenses decreased to $8.0 million from $10.2 million in Q1 2024, primarily due to lower stock-based compensation and reduced spending [7] Cash Flow and Losses - The net loss for Q1 2025 was $4.6 million, or negative $0.09 per diluted share, compared to a net loss of $8.1 million, or negative $0.20 per diluted share, in Q1 2024 [9][21] - Adjusted EBITDA improved to negative $2.5 million from negative $3.8 million year-over-year, while free cash flow was negative $4.3 million, an improvement from negative $6.7 million in Q1 2024 [10][27] Strategic Developments - The collaboration with Pluristyx, Inc. positions Teknova as the exclusive manufacturer and distributor of the PluriFreeze™ product line in the U.S. and Canada, expanding its market reach [1][8] - The company maintains a strong cash position with total cash and short-term investments of $26.3 million and total borrowings of $13.2 million at the end of Q1 2025 [8]

Core Viewpoint - Alpha Teknova, Inc. is set to report its financial results for Q1 2025 on May 8, 2025, after market close, indicating a focus on transparency and communication with investors [1]. Group 1: Financial Reporting - The company will announce its financial results for the first quarter ended March 31, 2025, on May 8, 2025 [1]. - A webcast and conference call will be held on the same day at 5 p.m. Eastern Time for investors to access the results [2]. Group 2: Company Overview - Teknova has been innovating in the manufacture of critical reagents since 1996, supporting the life sciences industry [3]. - The company offers customizable solutions for various stages of the workflow, aiding in molecular diagnostics, synthetic biology, and emerging therapeutic modalities [3]. - Teknova operates from a 180,000 square feet facility in Hollister, California, designed for efficient production of foundational ingredients for next-generation therapies [3].